Show simple item record

dc.contributor.authorGarcía Bea, Aintzane
dc.contributor.authorMiranda Azpiazu, Patricia
dc.contributor.authorMuguruza Millán, Carolina ORCID
dc.contributor.authorMarmolejo Martínez-Arteseroa, Sara
dc.contributor.authorDíez Alarcia, Rebeca ORCID
dc.contributor.authorGabilondo Urquijo, Ane Miren ORCID
dc.contributor.authorCallado Hernando, Luis Felipe ORCID
dc.contributor.authorMorentin Campillo, Benito
dc.contributor.authorGonzález Maeso, Javier
dc.contributor.authorMeana Martínez, José Javier ORCID
dc.date.accessioned2020-03-05T13:39:40Z
dc.date.available2020-03-05T13:39:40Z
dc.date.issued2019-12
dc.identifier.citationEuropean Neuropsychopharmacology 29(12) : 1453-1463 (2019)es_ES
dc.identifier.issn0924-977X
dc.identifier.issn1873-7862
dc.identifier.urihttp://hdl.handle.net/10810/41959
dc.description.abstractSerotonin 5-HT2A receptors (5-HT(2A)Rs) have been implicated in schizophrenia. However, postmortem studies on 5-HT(2A)Rs expression and functionality in schizophrenia are scarce. The 5-HT2AR mRNA and immunoreactive protein expression were evaluated in postmortem tissue from dorsolateral prefrontal cortex (DLPFC) of antipsychotic-free (n = 18) and antipsychotic-treated (n = 9) subjects with schizophrenia, and matched controls (n = 27). Functional coupling of 5-HT2AR to G-proteins was tested by measuring the activation induced by the agonist (+/-)-2,5-dimethoxy-4-iodoamphetamine hydrochloride ((+/-)DOI) in antibody-capture [S-35]GTP gamma S scintillation proximity assays (SPA). In antipsychotic-free schizophrenia subjects, 5-HT2AR mRNA expression and protein immunoreactivity in total homogenates was similar to controls. In contrast, in antipsychotic-treated schizophrenia subjects, lower mRNA expression (60 +/- 9% vs controls) and a trend to reduced protein immunoreactivity (86 +/- 5% vs antipsychotic-free subjects) just in membrane-enriched fractions was observed. [S-35]GTP gamma S SPA revealed a significant (similar to)6% higher stimulation of G(alpha i1)-protein by (+/-)DOI in schizophrenia, whereas activation of the canonical G(alpha q/11)-protein pathway by (+/-)DOI remained unchanged. Expression of G(alpha i1) - and G(alpha q/11)-proteins did not differ between groups. Accordingly, in rats chronically treated with clozapine, but not with haloperidol, a 30-40% reduction was observed in 5-HT2AR mRNA expression, 5-HT2AR protein immunoreactivity and [H-3]ketanserin binding in brain cortical membranes. Overall, the data suggest a supersensitive 5-HT2AR signaling through inhibitory G(alpha i1)-proteins in schizophrenia. Together with previous results, a dysfunctional pro-hallucinogenic agonist-sensitive 5-HT2AR conformation in postmortem DLPFC of subjects with schizophrenia is proposed. Atypical antipsychotic treatment would contribute to counterbalance this 5-HT2AR supersensitivity by reducing receptor expression. (C) 2019 The Author(s). Published by Elsevier B.V.es_ES
dc.description.sponsorshipThis study was supported by US National Institutes of Health (NIH) (R01 MH084894 and R01MH111940 to JG-M), Spanish Ministry of Science, Innovation and Universities and European ERDF Funds (SAF2009-08460 and 2017-88126-R to JJM), and the Basque Government (IT-616-13 and IT-1211-19 to JJM).es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/SAF2017-88126-Res_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/SAF2009-08460-Res_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectserotonin 2a receptores_ES
dc.subjectschizophreniaes_ES
dc.subjecthuman braines_ES
dc.subjectg proteines_ES
dc.subjectantipsychoticses_ES
dc.subjectlysergic-acid diethylamidees_ES
dc.subjectmessenger-rna expressiones_ES
dc.subject2a receptores_ES
dc.subjectprefrontal cortexes_ES
dc.subjectbindinges_ES
dc.subjectmodulationes_ES
dc.subjectdepressiones_ES
dc.subjectresponseses_ES
dc.titleSerotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via Gαi1-proteinses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder©2019 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/es_ES
dc.rights.holderAtribución-NoComercial-SinDerivadas 3.0 España*
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0924977X19317250?via%3Dihubes_ES
dc.identifier.doi10.1016/j.euroneuro.2019.10.013
dc.departamentoesEspecialidades médico-quirúrgicases_ES
dc.departamentoesFarmacologíaes_ES
dc.departamentoeuFarmakologiaes_ES
dc.departamentoeuMedikuntza eta kirurgia espezialitateakes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

©2019 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as ©2019 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/